Phibro Animal Health

Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets antibacterial, nutritional specialty products, and vaccines. The Mineral Nutrition segment consists of the formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

PAHC reports Q3 sales growth, addresses challenges and opportunities

PAHC's Q3 2023 earnings call highlighted strong sales growth in the Animal Health segment, while facing challenges in the Mineral Nutrition segment. The company reiterated its full-year guidance and discussed various opportunities for growth and expansion.

Phibro Animal Health reports Q2 growth, adjusts guidance for 2023

Phibro Animal Health (PAHC) showed overall growth in net sales and adjusted EBITDA despite challenges in certain regions and segments.
The company remains focused on its full-year guidance but adjusted GAAP expectations due to environmental factors.
Strategic investments and market opportunities present avenues for future growth and performance improvement.

Phibro Animal Health reports strong Q3 sales growth and margin improvement

Phibro Animal Health Corporation demonstrated robust sales growth and margin improvement in the Animal Health segment, while facing challenges related to negative free cash flow. Despite this, the company remains optimistic about meeting its full-year guidance and sees opportunities for growth through market expansion and operational enhancements.

Phibro Animal Health reports strong FY 2023 performance and projects continued growth in Animal Health segment

Phibro Animal Health delivered solid financial performance in FY 2023, with a strong outlook for FY 2024 driven by growth in the Animal Health segment.
Strategic investments in vaccines and companion animals position the company for continued expansion and margin maintenance amidst challenges.
Efforts to enhance operational efficiency and cash flow generation underscore a commitment to sustainable growth and financial strength.
Anticipated top and bottom-line growth, along with market stability, signal a positive trajectory for Phibro Animal Health in the upcoming fiscal year.

Phibro Animal Health reports mixed Q1 results amid market challenges

Phibro Animal Health's Q1 2024 performance was marked by growth in the Animal Health segment but challenges in other segments.
Efforts to manage working capital effectively and maintain a stable financial position are key strengths.
However, declines in adjusted EBITDA, revenue, and margins present hurdles that require strategic solutions.
Opportunities for growth lie in addressing challenges across segments and exploring innovative market strategies.

Phibro Animal Health reports Q2 growth, affirms guidance amid challenges

Phibro Animal Health's Q2 2024 performance reflects solid growth in net sales driven by the Animal Health segment, despite challenges in other segments.
The company's ability to manage operational challenges in Israel and maintain guidance reaffirm confidence in its strategic direction and resilience.
With positive demand trends and a new CFO onboard, Phibro Animal Health is poised to leverage opportunities for growth and operational excellence.

Phibro Animal Health reports robust Q3 performance and strategic acquisitions

Phibro Animal Health (PAHC) delivered a strong Q3 performance with notable growth in total company and Animal Health sales, supported by positive financial metrics and strategic acquisitions.
While facing integration challenges and competitive pressures, the company's strengths in market performance, financial health, and strategic guidance position it well for future growth.
Opportunities in product expansion, market diversification, and innovation present avenues for sustained growth and market leadership in the animal health industry.

Phibro Animal Health posts strong Q4 results, eyes Zoetis acquisition

Phibro Animal Health (PAHC) delivered robust financial results in Q4 2024, driven by growth in key segments and operational improvements.
The pending Zoetis MFA acquisition and successful refinancing demonstrate Phibro's strategic focus on expansion and financial strength.
While challenges in integration and regulatory approvals exist, Phibro is well-positioned to capitalize on opportunities for market expansion and sustained growth.
Investors can look forward to Phibro's continued performance and value creation as it navigates industry dynamics and executes on its strategic initiatives.

Phibro Animal Health reports stellar Q1 results and eyes growth

Phibro Animal Health delivered impressive Q1 2025 results, showcasing robust financial growth and strategic acquisitions.
While facing challenges such as margin concerns and project discontinuations, the company remains optimistic about its future prospects.
By capitalizing on opportunities in the acquired portfolio and focusing on operational excellence, Phibro aims to sustain its growth trajectory and drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets medicated feed additives, nutritional specialty products, and vaccines. The Mineral Nutrition segment includes formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.

Looking for a Growth Stock? 3 Reasons Why Phibro (PAHC) is a Solid Choice

Phibro (PAHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Phibro Animal Health Corporation (PAHC) Hits Fresh High: Is There Still Room to Run?

Explore Phibro's (PAHC) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Investing in Phibro (PAHC)? Don't Miss Assessing Its International Revenue Trends

Phibro Animal Health Corporation (NASDAQ:PAHC ) Q1 2025 Earnings Conference Call November 7, 2024 9:00 AM ET Company Participants Glenn David - Chief Financial Officer Jack Bendheim - Chairman-Board of Directors, President & Chief Executive Officer Daniel Bendheim - Director & Executive Vice President-Corporate Strategy Larry Miller - Chief Operating Officer Conference Call Participants Ekaterina Knyazkova - JPMorgan Michael Ryskin - Bank of America Navann Ty - BNP Paribas Operator Hello, and thank you for standing by. My name is Regina and I will be your conference operator today.

Phibro Animal Health Corporation (PAHC) Q1 2025 Earnings Call Transcript

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock

Abbott Labs

Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

PAHC or ABT: Which Is the Better Value Stock Right Now?

PAHC delivers strong growth across all its segments in the first quarter of fiscal 2025.

Phibro's Q1 Earnings Top Estimates, Stock Up, Net Sales Surge Y/Y

While the top- and bottom-line numbers for Phibro (PAHC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Phibro (PAHC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Phibro Animal Health (PAHC) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.14 per share a year ago.

Phibro Animal Health (PAHC) Tops Q1 Earnings Estimates

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended September 30, 2024 (compared to the three months ended September 30, 2023) Net sales of $260.4 million, an increase of $29.1 million, or 13% Net income of $7.0 million, an increase of $15.0 million Dil.

Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance

Brinker International

IAMGOLD

Leidos Hld

State Street

Stocks like IAG, LDOS, EAT, PAHC and STT are seeing price strength and have a high chance of carrying the momentum forward.

5 Stocks Trading Near 52-Week High With More Upside Potential

TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 18, 2024, to stockholders of record at the close of business on November 27, 2024. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner w.

Phibro Animal Health Corporation Declares Quarterly Dividend

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.

PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis

Zoetis

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the successful completion of the acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc. (NYSE:ZTS). This acquisition marks a significant step in furthering Phibro's purpose to optimize global animal health and nutrition for better lives and a more sustainable world. “Adding this new lineup of medicated feed additives and water-soluble products.

Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products

Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy?

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 6, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 7, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (88.

Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term

The stocks we learn to search for today are top-ranked momentum stocks that might be worth buying to close out October and throughout the last two months of 2024.

Finding Great Top-Ranked Momentum Stocks to Buy Now

Insulet

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Insulet (PODD). But which of these two stocks is more attractive to value investors?

PAHC vs. PODD: Which Stock Is the Better Value Option?

AllianceBernstein Hld

Carnival

Nordstrom

Jackson Financial

JWN, PAHC, AB, CCL and JXN are five stocks with explosive relative price strength.

Grab These 5 Relative Price Strength Stocks for Strong Returns

Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?

Equifax

Tencent Holdings Limited

TCEHY, EFX and PAHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 10, 2024.

Best Momentum Stock to Buy for October 10th

Carvana

Henkel AG & Co KGaA

Nexxen International Ltd

Sotherly Hotels

NEXN, CVNA, PAHC, SOHO and HENKY have been added to the Zacks Rank #1 (Strong Buy) List on October 10, 2024.

News for Phibro Animal Health Stock (PAHC)